The safety of vedolizumab for ulcerative colitis and Crohn's disease

Colombel, Jean‐Frédéric; E. Sands, Bruce; Rutgeerts, Paul; J. Sandborn, William; Danese, Silvio; D’Haens, Geert; Panaccione, Remo; V. Loftus, Edward; Sankoh, Serap; H. Fox, Irving; Parikh, Asit; Milch, Catherine; Abhyankar, Brihad; G. Feagan, Brian

doi:10.1136/gutjnl-2015-311079

Public

The safety of vedolizumab for ulcerative colitis and Crohn's disease

Published in Gut • Feb 18, 2016

Authors:

Jean‐Frédéric Colombel

Bruce E. Sands

Paul Rutgeerts

Abstract

OBJECTIVE: integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an integrated summary of the safety of vedolizumab. DESIGN: Safety data (May 2009-June 2013) from six trials of vedolizumab were integrated. Adverse events were evaluated in patients who received ≥1 ...

Subject

Vedolizumab

Medicine

Ulcerative colitis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!